Literature DB >> 17353246

Immunomodulatory effects of fosfomycin in experimental human endotoxemia.

Robert Sauermann1, Claudia Marsik, Ilka Steiner, Katja Seir, Tuende Cvitko, Markus Zeitlinger, Oswald Wagner, Christian Joukhadar.   

Abstract

To evaluate the effect of fosfomycin on proinflammatory cytokines, a bolus of 2 ng of bacterial lipopolysaccharide/kg of body weight was injected intravenously into healthy volunteers. After 2 h, subjects received 8 g of fosfomycin or placebo in a randomized crossover study design. The resulting concentrations of tumor necrosis factor alpha, interleukin-1beta (IL-1beta), and IL-6 expressed as protein and mRNA levels were almost identical with and without fosfomycin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353246      PMCID: PMC1855568          DOI: 10.1128/AAC.00914-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Immunological therapy of sepsis: experimental therapies.

Authors:  P Arndt; E Abraham
Journal:  Intensive Care Med       Date:  2001       Impact factor: 17.440

Review 2.  Immunological therapy in sepsis: currently available.

Authors:  J Carlet
Journal:  Intensive Care Med       Date:  2001       Impact factor: 17.440

3.  Variation in antibiotic use in the European Union.

Authors:  O Cars; S Mölstad; A Melander
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

4.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

5.  Safety of endotoxin challenge in healthy volunteers: bradycardia.

Authors:  Bernd Jilma
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

6.  Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production.

Authors:  K Morikawa; J Zhang; M Nonaka; S Morikawa
Journal:  Int J Antimicrob Agents       Date:  2002-01       Impact factor: 5.283

7.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

8.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

9.  Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

10.  Fosfomycin, an antibiotic, possessed TGF-beta-like immunoregulatory activities.

Authors:  S Ishizaka; H Takeuchi; M Kimoto; S Kanda; S Saito
Journal:  Int J Immunopharmacol       Date:  1998-12
View more
  6 in total

Review 1.  Of microbes and meals: the health consequences of dietary endotoxemia.

Authors:  Caleb J Kelly; Sean P Colgan; Daniel N Frank
Journal:  Nutr Clin Pract       Date:  2012-02-29       Impact factor: 3.080

Review 2.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  Value of caffeic acid phenethyl ester pretreatment in experimental sepsis model in rats.

Authors:  Ozlem Alici; Havva Sahin Kavakli; Cemile Koca; Neriman Defne Altintas; Murat Aydin; Suleyman Alici
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

4.  Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model.

Authors:  Caifen Qi; Shuangli Xu; Maomao Wu; Shuo Zhu; Yanyan Liu; Hong Huang; Guijun Zhang; Jiabin Li; Xiaohui Huang
Journal:  Infect Drug Resist       Date:  2019-11-12       Impact factor: 4.003

5.  In vitro and in vivo Antibacterial Activity of Linezolid Plus Fosfomycin Against Staphylococcus aureus with Resistance to One Drug.

Authors:  Na Xie; Lifang Jiang; Mingtao Chen; Guijun Zhang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Infect Drug Resist       Date:  2021-02-24       Impact factor: 4.003

Review 6.  The Interplay between Daptomycin and the Immune System.

Authors:  Theodoros Kelesidis
Journal:  Front Immunol       Date:  2014-02-12       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.